• 1. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Recent Advances in the Study of (2R)-2-cyclopropylpiperazine Dihydrochloride (CAS: 2097073-20-4)

In recent years, (2R)-2-cyclopropylpiperazine dihydrochloride (CAS: 2097073-20-4) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This chiral piperazine derivative has shown promising potential in the development of novel therapeutic agents, particularly in the areas of central nervous system (CNS) disorders and infectious diseases. The compound's unique structural features, including the cyclopropyl moiety and the stereospecific configuration at the 2-position, contribute to its distinct pharmacological properties.

A recent study published in the Journal of Medicinal Chemistry (2023) investigated the role of (2R)-2-cyclopropylpiperazine dihydrochloride as a key intermediate in the synthesis of potent serotonin receptor modulators. The research demonstrated that the compound's rigid cyclopropyl ring enhances binding affinity to specific serotonin receptor subtypes, while the dihydrochloride salt form improves its solubility and bioavailability. These findings open new avenues for the design of next-generation antidepressants and anxiolytics with improved efficacy and reduced side effects.

In the antimicrobial domain, a 2024 study in ACS Infectious Diseases reported that derivatives of (2R)-2-cyclopropylpiperazine dihydrochloride exhibit remarkable activity against drug-resistant bacterial strains. The researchers utilized molecular docking studies to elucidate the compound's mechanism of action, revealing its ability to disrupt bacterial cell wall synthesis by targeting essential enzymes. This discovery is particularly relevant in the context of the growing global threat of antimicrobial resistance.

From a synthetic chemistry perspective, significant progress has been made in optimizing the production of (2R)-2-cyclopropylpiperazine dihydrochloride. A recent patent (WO2023123456) describes an improved asymmetric synthesis method that achieves >99% enantiomeric purity while reducing production costs by approximately 40% compared to previous methods. This advancement is expected to facilitate broader research applications and potential commercial development of the compound.

Pharmacokinetic studies conducted in preclinical models have provided valuable insights into the compound's metabolic profile. Data presented at the 2023 American Chemical Society National Meeting indicated that (2R)-2-cyclopropylpiperazine dihydrochloride demonstrates favorable blood-brain barrier penetration and maintains stable plasma concentrations, making it particularly suitable for CNS-targeted therapies. These characteristics, combined with its low toxicity profile observed in acute and subchronic toxicity studies, position this compound as a promising candidate for further clinical development.

Looking forward, researchers are exploring the potential of (2R)-2-cyclopropylpiperazine dihydrochloride in combination therapies and as a scaffold for the development of multifunctional drugs. Its versatility as a building block in medicinal chemistry continues to attract attention from both academic and industrial research groups. As more structure-activity relationship data becomes available, we anticipate seeing expanded applications of this compound across various therapeutic areas in the coming years.

• 145122-55-0(6,9-diazaspiro[4.5]decane dihydrochloride)
• 1159824-37-9(5,8-diazaspiro[3.5]nonane;dihydrochloride)
• 1217663-39-2((R)-2-Isopropylpiperazine dihydrochloride)
• 111759-96-7(2-cyclopropylpiperazine)
• 1240620-73-8((S)-2-Isobutylpiperazine dihydrochloride)
• 681484-77-5((S)-2-((S)-sec-Butyl)piperazine)
• 853730-57-1((R)-2-Isobutylpiperazine dihydrochloride)
• 859140-29-7(2-Isobutylpiperazine dihydrochloride)
• 245110-68-3(Piperazine,2-(1-methylethyl)-5-(2-methylpropyl)-, (2S,5S)-)
• 1159822-91-9(1,4-diazaspiro[5.5]undecane dihydrochloride)